ABBV goes into Thursday's Q2 report having already cleared most of the analyst target cluster — the question now is whether the numbers can hold the stock at altitude.
The broader positioning picture is remarkably calm for a company three days from a major print. Borrow availability is essentially unlimited, with over 1.2 billion shares available to lend and cost-to-borrow at just 0.21% — down more than 50% over the past month. Short interest ticked up sharply on July 24, rising 16.6% in a single session to 1.31% of the free float, but that follows weeks of covering and the absolute level remains near the lowest of the year. Options traders are equally relaxed: the put/call ratio runs at 0.785, almost exactly in line with its 20-day average, with a z-score near zero. None of the defensive hedging that typically accumulates before a high-stakes print is visible here. The stock itself pulled back less than 1% on Monday to $256.91, trimming slightly from the $259 level reached last week, but the one-month gain holds above 1.4%.
The analyst debate has one dominant direction: up. Every target change since July 6 has been an increase. JP Morgan raised to $280, Wells Fargo to $295, BMO to $300, RBC to $280. The cautious outliers — Citigroup and UBS, both at Neutral with $260 targets — are now effectively at-the-money after the stock broke through $260. The consensus mean of $267.79 implies just 4% further upside from current levels, a gap that has compressed sharply from the 10%-plus implied upside that characterized the setup a month ago. Bulls point to Skyrizi and Rinvoq as franchise-level drivers, the pipeline of over 90 compounds, and a 12-month forward EPS growth factor that ranks in the 99th percentile of the universe. Bears frame the same data differently: Imbruvica faces mounting competitive pressure, valuation is no longer cheap at roughly 17x earnings, and the price-to-book has run to over 100x on the back of acquisitions that still need to prove out. The EPS surprise factor — ranked in just the 9th percentile — is worth noting; AbbVie has not been a consistent beat-and-raise name on that metric.
Institutional ownership is concentrated and stable. BlackRock holds 8.5% of shares, with Capital Research adding over 11 million shares in the most recent reported period. That kind of large-cap anchor ownership tends to dampen volatility around prints but also limits the upside momentum from fresh institutional buying. The two most recent earnings events tell a split story: Q1 delivered a 6.9% one-day gain, while the May print produced barely a 0.03% move — a reminder that even a clean quarter doesn't guarantee a clean reaction when the setup is already well-owned and well-telegraphed.
The Q2 print will test whether Skyrizi and Rinvoq growth is running ahead of the already-elevated analyst expectations baked into a stock that has gained more than 20% in six weeks.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
ABBV has added another $1.60 since Sunday's recovery note and now trades at $256.10 — six days from a Q2 earnings print that has become the most anticipated catalyst on the pharma calendar this month. The analyst…
ABBV closed Tuesday at $244.78, down 4% from the July 10 close cited in last week's note — and the Street's response has been to keep raising targets anyway. The analyst upgrade wave that defined last week's story has…
